2023 World Conference on Lung Cancer (Posters)-EP07.04. Real-World Data Based on EGFR Mutation Status in Early-Stage NSCLC

Pdf Summary

A study presented at the WCLC 2023 conference investigated the survival impact and genomic landscape of EGFR mutations in early-stage non-small cell lung cancer (NSCLC). The study included 1,725 patients with stage IA-IIIB NSCLC who underwent curative intent resection between 2009 and 2020. The primary objective was to investigate the survival impact of EGFR mutation status in stage IA-IIIB NSCLC. <br /><br />The results showed that 50% of patients harbored EGFR mutations, with E19del being the most common mutation. The study also found that patients with earlier stages of NSCLC (IA1-IB) were more likely to have EGFR mutations compared to patients with stage II and III disease. However, there was no statistically significant difference in survival based on EGFR mutation status in the overall population or based on stage.<br /><br />Next-generation sequencing was performed on 189 patients, revealing frequent mutations in TP53, BRCA, KRAS, and PIK3CA. Importantly, certain genes (KRAS, ALK, CDKN2A, and SOX2) were differentially expressed between the EGFR mutant and wild-type NSCLC patient groups and showed mutual exclusivity in EGFR mutant NSCLC.<br /><br />Overall, the study concludes that there is no statistically significant difference in recurrence-free survival between the EGFR mutant and wild-type early-stage NSCLC patient groups. However, it did confirm that EGFR mutations are more frequently found in earlier stages of NSCLC. These findings provide valuable insights into the role of EGFR mutations in early-stage NSCLC and the genomic landscape of these tumors.

Asset Subtitle

Ji Hyung Hong

Meta Tag

Speaker Ji Hyung Hong

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

WCLC 2023 conference

survival impact

genomic landscape

EGFR mutations

early-stage non-small cell lung cancer

NSCLC

curative intent resection

E19del

stage IA-IIIB

next-generation sequencing